Literature DB >> 17197105

Further characterization of a rat model of varicella zoster virus-associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs.

F S Hasnie1, J Breuer, S Parker, V Wallace, J Blackbeard, I Lever, P R Kinchington, A H Dickenson, T Pheby, A S C Rice.   

Abstract

Persistent herpes zoster-associated pain is a significant clinical problem and an area of largely unmet therapeutic need. Progress in elucidating the underlying pathophysiology of zoster-associated pain and related co-morbidity behavior, in addition to appropriately targeted drug development has been hindered by the lack of an appropriate animal model. This study further characterizes a recently developed rat model of zoster-associated hypersensitivity and investigates (a) response to different viral strains; (b) relationship between viral inoculum concentration ('dose') and mechanical hypersensitivity ('response'); (c) attenuation of virus-associated mechanical hypersensitivity by clinically useful analgesic drugs; and (d) measurement of pain co-morbidity (anxiety-like behavior) and pharmacological intervention in the open field paradigm (in parallel with models of traumatic peripheral nerve injury). Varicella zoster virus was propagated on fibroblast cells before s.c. injection into the glabrous footpad of the left hind limb of adult male Wistar rats. Control animals received injection of uninfected fibroblast cells. Hind-limb reflex withdrawal thresholds to mechanical, noxious thermal and cooling stimuli were recorded at specified intervals post-infection. Infection with all viral strains was associated with a dose-dependent mechanical hypersensitivity but not a thermal or cool hypersensitivity. Systemic treatment with i.p. morphine (2.5 mg/kg), amitriptyline (10 mg/kg), gabapentin (30 mg/kg), (S)-(+)-ibuprofen (20 mg/kg) and the cannabinoid WIN55,212-2 (2 mg/kg) but not the antiviral, acyclovir (50 mg/kg), was associated with a reversal of mechanical paw withdrawal thresholds. In the open field paradigm, virus-infected and nerve-injured animals demonstrated an anxiety-like pattern of ambulation (reduced entry into the central area of the open arena) which was positively correlated with mechanical hypersensitivity. This may reflect pain-related co-morbidity. Further, anxiety-like behavior was attenuated by acute i.p. administration of gabapentin (30 mg/kg) in nerve-injured, but not virus-infected animals. This model will prove useful in elucidating the pathophysiology of zoster-associated pain and provide a tool for pre-clinical screening of analgesic drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17197105      PMCID: PMC2394505          DOI: 10.1016/j.neuroscience.2006.11.029

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  51 in total

Review 1.  What should we be measuring in behavioral studies of chronic pain in animals?

Authors:  Jeffrey S Mogil; Sara E Crager
Journal:  Pain       Date:  2004-11       Impact factor: 6.961

2.  Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala.

Authors:  Minoru Narita; Chihiro Kaneko; Kan Miyoshi; Yasuyuki Nagumo; Naoko Kuzumaki; Mayumi Nakajima; Kana Nanjo; Kiyomi Matsuzawa; Mitsuaki Yamazaki; Tsutomu Suzuki
Journal:  Neuropsychopharmacology       Date:  2006-04       Impact factor: 7.853

3.  The anticonvulsant compound gabapentin possesses anxiolytic but not amnesic effects in rats.

Authors:  F de-Paris; J V Busnello; M R Vianna; J B Salgueiro; J Quevedo; I Izquierdo; F Kapczinski
Journal:  Behav Pharmacol       Date:  2000-04       Impact factor: 2.293

4.  Behavioural measures of depression and anxiety in rats with spinal nerve ligation-induced neuropathy.

Authors:  V K Kontinen; T Kauppila; S Paananen; A Pertovaara; E Kalso
Journal:  Pain       Date:  1999-03       Impact factor: 6.961

Review 5.  Clinical features and pathophysiologic mechanisms of postherpetic neuralgia.

Authors:  T Nurmikko
Journal:  Neurology       Date:  1995-12       Impact factor: 9.910

6.  A double-blind, placebo-controlled study of oral acyclovir in postherpetic neuralgia.

Authors:  O S Surman; T Flynn; R T Schooley; L Baer; S Parker; M S Hirsch; L G Davis
Journal:  Psychosomatics       Date:  1990       Impact factor: 2.386

7.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

8.  Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat.

Authors:  Maria Schäfers; Martin Marziniak; Linda S Sorkin; Tony L Yaksh; Claudia Sommer
Journal:  Exp Neurol       Date:  2004-01       Impact factor: 5.330

9.  Behavioral manifestations of an experimental model for peripheral neuropathy produced by spinal nerve ligation in the primate.

Authors:  S M Carlton; H A Lekan; S H Kim; J M Chung
Journal:  Pain       Date:  1994-02       Impact factor: 6.961

Review 10.  Analgesic therapy in postherpetic neuralgia: a quantitative systematic review.

Authors:  Kathleen Hempenstall; Turo J Nurmikko; Robert W Johnson; Roger P A'Hern; Andrew S C Rice
Journal:  PLoS Med       Date:  2005-07-26       Impact factor: 11.069

View more
  48 in total

Review 1.  Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.

Authors:  Christopher Eccleston; Tess E Cooper; Emma Fisher; Brian Anderson; Nick Mr Wilkinson
Journal:  Cochrane Database Syst Rev       Date:  2017-08-02

2.  A single subanesthetic dose of ketamine relieves depression-like behaviors induced by neuropathic pain in rats.

Authors:  Jing Wang; Yossef Goffer; Duo Xu; David S Tukey; D B Shamir; Sarah E Eberle; Anthony H Zou; Thomas J J Blanck; Edward B Ziff
Journal:  Anesthesiology       Date:  2011-10       Impact factor: 7.892

Review 3.  Gene therapy for the treatment of chronic peripheral nervous system pain.

Authors:  William F Goins; Justus B Cohen; Joseph C Glorioso
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

4.  Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol.

Authors:  Joshua A Lile; Michael J Wesley; Thomas H Kelly; Lon R Hays
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

5.  Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity.

Authors:  I J Lever; T M Pheby; A S C Rice
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

Review 6.  Herpes zoster and postherpetic neuralgia: past, present and future.

Authors:  Gary J Bennett; C Peter N Watson
Journal:  Pain Res Manag       Date:  2009 Jul-Aug       Impact factor: 3.037

Review 7.  Non-steroidal anti-inflammatory drugs (NSAIDs) for cancer-related pain in children and adolescents.

Authors:  Tess E Cooper; Lauren C Heathcote; Brian Anderson; Marie-Claude Grégoire; Gustaf Ljungman; Christopher Eccleston
Journal:  Cochrane Database Syst Rev       Date:  2017-07-24

8.  Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain.

Authors:  Victoria C J Wallace; Julie Blackbeard; Andrew R Segerdahl; Fauzia Hasnie; Timothy Pheby; Stephen B McMahon; Andrew S C Rice
Journal:  Brain       Date:  2007-08-30       Impact factor: 13.501

Review 9.  Improving the translation of analgesic drugs to the clinic: animal models of neuropathic pain.

Authors:  N Percie du Sert; A S C Rice
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

Review 10.  Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain.

Authors:  Paola Sacerdote; Silvia Franchi; Sarah Moretti; Mara Castelli; Patrizia Procacci; Valerio Magnaghi; Alberto E Panerai
Journal:  J Neuroimmune Pharmacol       Date:  2012-12-16       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.